Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D. - Yahoo Finance

October 28, 2022 astatine 1pm ET, 10am PT

Shareholders are invited to taxable questions to the CEO

PEARL RIVER, N.Y., October 21, 2022--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) volition clasp a virtual, video Q&A with its CEO, Ron Cohen, M.D., connected Friday, October 28 astatine 1:00pm ET, 10:00am PT.

The telephone volition reappraisal the items connected the ballot for Acorda’s Special Meeting of Shareholders connected November 4, 2022. Participants volition beryllium capable to taxable questions to Dr. Cohen, which helium volition code live.

Video Q&A Participation Instructions

To enactment successful the video event:

• Click the nexus beneath from a laptop oregon mobile device. (Mobile instrumentality users volition beryllium prompted to download the BlueJeans app.)
  https://primetime.bluejeans.com/a2m/live-event/rraraavy

• If prompted, participate the pursuing case-sensitive Event ID: rraraavy

To enactment implicit the phone:

• Dial 1-800-520-9950 (US: Toll Free)

• Enter Meeting ID: 4091564#

• Smartphone users tin click connected the pursuing nexus to automatically beryllium connected:
  800-520-9950,,, 4091564#

To taxable a question:

• Prior to the Q&A, questions tin beryllium emailed to investorrelations@acorda.com.

• During the unrecorded Q&A, questions tin beryllium typed into the BlueJeans chat window.

How Shareholders Can Vote:

Stockholders are encouraged to formed your ballot promptly FOR the Reverse Split connection without further delay.

By phone: Call 1-800-967-5051, Monday – Friday 9am to 10pm ET; Saturday 10am – 6pm ET. If you telephone aft hours, permission a connection and the telephone halfway volition telephone you backmost the adjacent day.

Online: www.proxyvote.com Please person the power fig that was sent to you successful the mail.

Mail: Sign, date, and instrumentality your proxy paper successful the postage-paid, stamped envelope provided.

About Acorda Therapeutics

Acorda Therapeutics develops therapies to reconstruct relation and amended the lives of radical with neurological disorders. INBRIJA^® is approved for intermittent attraction of OFF episodes successful adults with Parkinson’s illness treated with carbidopa/levodopa. INBRIJA is not to beryllium utilized by patients who instrumentality oregon person taken a nonselective monoamine oxidase inhibitor specified arsenic phenelzine oregon tranylcypromine wrong the past 2 weeks. INBRIJA utilizes Acorda’s innovative ARCUS^® pulmonary transportation system, a exertion level designed to present medicine done inhalation. Acorda besides markets the branded AMPYRA^® (dalfampridine) Extended Release Tablets, 10 mg.

Forward-Looking Statements

This property merchandise includes forward-looking statements. All statements, different than statements of humanities facts, regarding management's expectations, beliefs, goals, plans oregon prospects should beryllium considered forward-looking. These statements are taxable to risks and uncertainties that could origin existent results to disagree materially, including: we whitethorn not beryllium capable to successfully marketplace AMPYRA, INBRIJA oregon immoderate different products nether development; the COVID-19 pandemic, including related restrictions connected in-person interactions and travel, and the imaginable for illness, quarantines and vaccine mandates affecting our management, employees oregon consultants oregon those that enactment for different companies we trust upon, could person a worldly adverse effect connected our concern operations oregon merchandise sales; our quality to pull and clasp cardinal absorption and different personnel, oregon support entree to adept advisors; our quality to rise further funds to concern our operations, repay outstanding indebtedness oregon fulfill different obligations, and our quality to power our costs oregon trim planned expenditures; risks associated with the trading of our communal stock, including the imaginable delisting of our communal banal from the Nasdaq Global Select Market and actions that we whitethorn take, specified arsenic a reverse banal split, successful bid to effort to support specified listing; risks related to our firm restructurings, including our quality to outsource definite operations, recognize expected outgo savings and support the workforce needed for continued operations; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could impact whether we person capable commercialized proviso of INBRIJA oregon AMPYRA to conscionable marketplace demand; our reliance connected third-party manufacturers for the timely accumulation of commercialized supplies of INBRIJA and AMPYRA; third-party payers (including governmental agencies) whitethorn not reimburse for the usage of INBRIJA oregon AMPYRA astatine acceptable rates oregon astatine each and whitethorn enforce restrictive anterior authorization requirements that bounds oregon artifact prescriptions; reliance connected collaborators and distributors to commercialize INBRIJA and AMPYRA extracurricular the U.S.; our quality to fulfill our obligations to distributors and collaboration partners extracurricular the U.S. relating to commercialization and proviso of INBRIJA and AMPYRA; contention for INBRIJA and AMPYRA, including expanding contention and accompanying nonaccomplishment of revenues successful the U.S. from generic versions of AMPYRA (dalfampridine) pursuing our nonaccomplishment of patent exclusivity; the quality to recognize the benefits anticipated from acquisitions because, among different reasons, acquired improvement programs are mostly taxable to each the risks inherent successful the cause improvement process and our cognition of the risks specifically applicable to acquired programs mostly improves implicit time; the hazard of unfavorable results from aboriginal studies of INBRIJA (levodopa inhalation powder) oregon from different probe and improvement programs, oregon immoderate different acquired oregon in-licensed programs; the occurrence of adverse information events with our products; the result (by judgement oregon settlement) and costs of legal, administrative oregon regulatory proceedings, investigations oregon inspections, including, without limitation, collective, typical oregon class-action litigation; nonaccomplishment to support our intelligence property, to support against the intelligence spot claims of others oregon to get third-party intelligence spot licenses needed for the commercialization of our products; and nonaccomplishment to comply with regulatory requirements could effect successful adverse enactment by regulatory agencies.

These and different risks are described successful greater item successful our filings with the Securities and Exchange Commission. We whitethorn not really execute the goals oregon plans described successful our forward-looking statements, and investors should not spot undue reliance connected these statements. Forward-looking statements made successful this property merchandise are made lone arsenic of the day hereof, and we disclaim immoderate intent oregon work to update immoderate forward-looking statements arsenic a effect of developments occurring aft the day of this property release, but arsenic whitethorn beryllium required by law.

View root mentation connected businesswire.com: https://www.businesswire.com/news/home/20221021005074/en/

Contacts

Tierney Saccavino
(914) 326-5104
tsaccavino@acorda.com